HVA in the Treatment of Mixed-Phenotype Acute Leukemia(MPAL).

This study aims to evaluate the safety and efficacy of homoharringtonine combined with venetoclax and azacitidine regimen (HVA) in newly diagnosed MPAL patients, providing a basis for the use of the HVA regimen in the treatment of MPAL.

NCT Number	NCT07517510
Lead Sponsor	Guangdong Second Provincial General Hospital Collaborators: Nanfang Hospital, Southern Medical University, Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University, First Affiliated Hospital of Guangxi Medical University, Guangzhou First People's Hospital, Zhongshan People's Hospital, Guangdong, China, Dongguan People's Hospital, Shenzhen Second People's Hospital
Conditions	Newly Diagnosed Mixed Phenotype Acute Leukemia (MPAL)
Enrollment	40 participants
Start Date	2026-04-01
Primary Completion	2026-12-31 (estimated)
Study Completion	2027-12-31 (estimated)
Updated on ClinicalTrials.gov	2026-04-08